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errors, but is a need of incorporating a more accurate 
algorithm for patients in which low density regions are 
involved. In fact we note a discrepancy between measured 
and planned dose in thoracic cases. It is due to the DC Pencil 
beam algorithm of dose reconstruction, that over-estimates 
dose in heterogeneous area. 
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In the framework of multimodality approaches combined 
radiochemotherapy for selected patients with bladder cancer 
already is accepted as alternative to radical cystectomy. 
Overall survival rates after five and ten years are 
comparable. The multimodality bladder preservation 
approach will be successful only in institutions with a close 
cooperation between urooncological and radiooncological 
partners. Combined radiochemotherapy is superior to 
radiation alone and therefore in a curative setting the use of 
simultaneous chemotherapy is mandatory. Further 
developments, e.g. brachytherapy, additional regional 
hyperthermia, the optimization of simultaneous 
chemotherapy, and the use of predictive biomarkers may 
further increase the results after organ-preserving 
multimodality treatment for patients with bladder cancer.  
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The therapeutic window of radiotherapy could be improved if 
tumor cells could be selectively rendered more sensitive to 
radiation. Such a strategy depends upon exploiting tumor 
specific targets, some of which, such as hypoxia in the 
microenvironment are well known, but many of which remain 
to be identified. The colony forming assay (CFA) is the ‘gold 
standard’ method for assessing intrinsic radiosensitivity in 
vitro. We have developed a technique to perform high-
throughput CFAs in 96 well plates and have recently 
completed siRNA screens of a selected DNA repair library and 
of approximately 10,000 additional genes, of which the 793 
gene ‘kinase’ section of the library has been examined in 
detail. The screens used a ranked-product analysis to identify 
the top hits. On the basis of the top candidate genes 
identified by the primary screen, a secondary library was 
then screened on multiple occasions. This work identified 
several genes such as ATM, ATR, DNA-PK and CHEK1, which 
are well known to play key roles in tumor cell 
radiosensitivity. In addition, we identified several novel 
genes whose depletion induced HeLa radiosensitisation in 6-
well plate CFAs. These experiments were repeated with 
separate siRNAs to ensure these findings were not the result 
of off-target effects. Depletion of these genes appeared to 
cause radiosensitisation in several other tumor cell lines as 
well. We are currently investigating the effects of several of 
these genes in greater detail. Ongoing work will be presented 
that clarifies the effects of gene knockdown on radio- in 
several tumor and normal tissue lines. The mechanism by 
which this knockdown causes these effects will also be 
presented for some of the targets. Tumor hypoxia is probably 
the major determinant of clinical outcome other than 
intrinsic radiosensitivity. Most work so far has concentrated 
on vascular effects in oxygen delivery as a determinant of 
this, but in fact oxygen consumption by the tumor cells is 
also a determinant of tumor oxygen concentration. We have 
developed screens for oxygen consumption. We used both the 
Pharmakon 1600 and Oncology drug set libraries for the 
screening. Our primary screen identified 100 compounds that 
reduced oxygen consumption (OCR) without significantly 
affecting cell death in FaDu hypopharyngeal cells. A 
secondary screen identified 50 compounds that reduced 
oxygen consumption (OCR) without significantly affecting cell 
death in either FaDu hypopharyngeal cells or MRC5 lung 
fibroblasts. The results of these “microenvironmental” 
screens will also be discussed.  
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The availability of Monte Carlo (MC)-based codes optimized 
for photon and electron beams in patient-specific geometries 
has lead to the development of several different MC-based 
dose calculation systems for radiotherapy treatment 
planning. MC-based photon beam dose calculations today are 
performed within minutes in the routine clinical setting.  As 
MC-based planning systems become more widely utilized in 
the clinic, it is critical that paradigms and approaches for 
clinical commissioning and implementation of these systems 
be formulated and discussed.  This lecture will focus on such 
strategies in the context of MC calculations for external 
photon and electron beam radiotherapy.  The following 
topics will be covered: (a) Overview of the MC method for 
radiotherapy photon beam simulation; (b) Review of the 
methods used for characterization of the linear accelerator 
(linac) and patient simulation; (c) Techniques for 
commissioning and experimental verification of MC-based 
dose calculation systems, and associated challenges; (d) 
Tools for facilitating MC-based treatment planning in the 
clinical setting, e.g. methods for viewing of isodose plans 
with their combined statistical uncertainty distributions; (e) 
Issues specific to MC-based electron beam dose calculations.  
